Related Experiment Video
Updated: Feb 25, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability
Nan Zhou1, Yugang Yan2, Chunxi Liu3
1Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong 250012, PR China; Drug Research and Development Center, Shandong Drug and Food Vocational College, Weihai, Shandong 264210, PR China.
Abstract:
Histone deacetylase inhibitors with desirable pharmacokinetic profiles which can be delivered to solid tumor tissues in large amount might be promising to treat solid tumor effectively. Herein, structural modification of a previously reported tetrahydroisoquinoline-based HDAC inhibitor 1 was carried out to improve its plasma stability for more feasible drug delivery. Among three newly synthesized analogs, the in vitro rat plasma stability of compound 2 (t1/2=630min) was over 5-fold improved than its parent 1 (t1/2=103min). In vitro activity evaluation showed that compound 2 and 1 exhibited similar HDACs inhibitory activity, which was validated by western blot analysis and antiproliferative assay. Moreover, compared with 1, compound 2 exhibited comparable, if not higher, in vivo antitumor activity in a human breast carcinoma (MDA-MB-231) xenograft model.
More Related Videos
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Antihypertensive Drugs: Thiazide-Class Diuretics
Pharmacogenomics: Identification of New Drug Targets
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

